UBS Group AG
- SEC CIK
- 0001610520
- Latest filing
- Aug 13, 2026
RVNC holding history
Revance Therapeutics, Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
RVNC overviewAll 13F holders of RVNCFull Q2 2026 holdings
- Shares (Q1 2025)
- 0
- Sold out in Q1 2025
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 16
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q1 2025 | 0 | $0 | 0.0% | −1,483,040−100.0% | Sold out | Holders |
| Q4 2024 | 1,483,040 | $4.51M | <0.1% | +850,487+134.5% | Added | Holders |
| Q3 2024 | 632,553 | $3.28M | <0.1% | +581,780+1,145.8% | Added | Holders |
| Q2 2024 | 50,773 | $130.5K | <0.1% | −139,419−73.3% | Reduced | Holders |
| Q1 2024 | 190,192 | $935.7K | <0.1% | −3,961−2.0% | Reduced | Holders |
| Q4 2023 | 194,153 | $1.71M | <0.1% | +76,108+64.5% | Added | Holders |
| Q3 2023 | 118,045 | $1.35M | <0.1% | −11,980−9.2% | Reduced | Holders |
| Q2 2023 | 130,025 | $3.29M | <0.1% | −1,264−1.0% | Reduced | Holders |
| Q1 2023 | 131,289 | $4.23M | <0.1% | +58,464+80.3% | Added | Holders |
| Q4 2022 | 72,825 | $1.34M | <0.1% | −9,937−12.0% | Reduced | Holders |
| Q3 2022 | 82,762 | $2.23M | <0.1% | −4,147−4.8% | Reduced | Holders |
| Q2 2022 | 86,909 | $1.20M | <0.1% | −2,361−2.6% | Reduced | Holders |
| Q1 2022 | 89,270 | $1.74M | <0.1% | +4,615+5.5% | Added | Holders |
| Q4 2021 | 84,655 | $1.38M | <0.1% | +23,374+38.1% | Added | Holders |
| Q3 2021 | 61,281 | $1.71M | <0.1% | +8,099+15.2% | Added | Holders |
| Q2 2021 | 53,182 | $1.58M | <0.1% | −952−1.8% | Reduced | Holders |
| Q1 2021 | 54,134 | $1.51M | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.